Paras Healthcare IPO 2026: GMP Today, Subscription Status, Price Band and Listing Date

Paras Healthcare IPO 2026: Latest Update

Paras Healthcare Limited's IPO has entered its final day of bidding on October 23, 2026. The ₹1,450 crore mainboard offering has attracted investor attention because of its established hospital network, specialised healthcare services and planned expansion.

The public issue opened on October 21 and comprises a ₹500 crore fresh issue and a ₹950 crore offer for sale (OFS). The company plans to use a significant portion of the fresh issue proceeds for debt repayment and investment in its subsidiary.

However, the IPO has witnessed a relatively cautious subscription response compared with some other large offerings in the market. Retail investor demand has been stronger than institutional participation in the reported early subscription figures.

Investors are monitoring the final-day bidding trend, grey market premium and potential listing performance as the subscription window approaches its close.

Paras Healthcare IPO Details

The minimum retail application amount is calculated using one lot of 21 shares at the upper price band.

Paras Healthcare IPO GMP Today

Paras Healthcare IPO's grey market premium has remained a closely watched indicator during the bidding period.

On October 22, market coverage reported a GMP of approximately ₹25 per share, equivalent to around a 4% premium over the upper issue price.

The ₹25 GMP is an earlier reported market snapshot and should not be treated as a verified live quote for October 23.

Grey market premiums are unofficial and can fluctuate throughout the day. The actual listing price may be higher or lower than these estimates, and a positive GMP does not guarantee listing gains.

Paras Healthcare IPO Subscription Status

Paras Healthcare IPO received a modest response during its initial bidding sessions.

The following figures represent reported subscription snapshots and are not the final closing-day numbers.

Subscription figures can differ across reporting snapshots and data providers. Investors should refer to the latest exchange figures for the accurate final subscription status.

Retail demand improved during the bidding period, but institutional participation remained limited in the reported updates.

A lower subscription level does not necessarily determine the company's long-term prospects, although it can reflect investor appetite, valuation concerns or prevailing market conditions.

About Paras Healthcare Limited

Paras Healthcare Limited operates under the Paras Health brand and provides tertiary and quaternary healthcare services across North India, Bihar and Jharkhand.

As of June 30, 2026, the company operated eight hospitals with a combined bed capacity of 2,211 beds.

Its hospital network includes locations in Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar.

The company focuses on specialised medical fields, including:

• Cardiac sciences

• Oncology and cancer care

• Neurosciences

• Gastro sciences

• Orthopaedics and sports injury

• Renal sciences

These specialities accounted for approximately 75.30% of its revenue in FY2026, according to reported IPO coverage.

Its specialised treatment capabilities and regional presence are important parts of its healthcare business model.

Paras Healthcare IPO Financial Performance

Paras Healthcare reported an improvement in revenue and profitability in FY2026.

The company recorded approximately 24% year-on-year growth in total income, while its profitability improved from a loss to a profit.

This turnaround is an important financial development for the hospital operator.

Investors should nevertheless examine operating margins, cash flow, borrowings, interest expenses and hospital-level performance to determine whether the improvement can continue.

Paras Healthcare IPO Objectives

The company plans to use the net proceeds from the fresh issue for debt reduction and general corporate requirements.

The disclosed objectives include:

• Debt repayment: Approximately ₹320.90 crore towards repayment or prepayment of certain company borrowings.

• Subsidiary investment: Approximately ₹54.10 crore for investment in Plus Medicare Hospitals Private Limited to support repayment or prepayment of its borrowings.

• General corporate purposes: The remaining eligible proceeds will be used for corporate needs.

The proposed debt reduction could help lower interest expenses and improve financial flexibility.

However, hospital expansion and medical infrastructure investments require substantial capital, making efficient fund management important for future growth.

Paras Healthcare Expansion Plans

Paras Healthcare has outlined plans to strengthen its hospital network and expand its capacity.

The company has proposed a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana.

Its planned expansion could increase total hospital capacity to approximately 3,011 beds by March 2028, according to offer-related disclosures.

Expansion may create opportunities for higher patient volumes and revenue growth.

However, new hospitals require investment in buildings, medical equipment, staffing and operational infrastructure. The time required to achieve healthy occupancy and profitability remains an important consideration.

Paras Healthcare IPO Anchor Investors

Paras Healthcare raised approximately ₹652.5 crore from anchor investors before the public issue opened.

The anchor book reportedly included domestic and international institutional investors.

Anchor participation can provide insight into institutional interest, but it does not guarantee listing gains or long-term stock performance.

Investors should evaluate the company's fundamentals and valuation independently rather than relying solely on anchor allocations.

Paras Healthcare IPO: Growth Opportunities

Rising healthcare demand: Growing demand for specialised treatment may support patient volumes.

Hospital network expansion: Planned facilities could strengthen its geographical reach.

Improved occupancy: Higher utilisation of existing hospital beds can support operating efficiency.

Specialised treatment services: Advanced medical capabilities may help the company compete in complex healthcare segments.

Financial recovery: The reported FY2026 profit turnaround may support investor confidence if sustained.

These growth opportunities depend on execution, doctor retention, patient demand and cost control.

Risks of Investing in Paras Healthcare IPO

Investors should consider the following risks before applying:

• Debt exposure: Borrowings can increase interest expenses and financial pressure.

• Expansion execution: New hospital projects may face delays or cost overruns.

• Competition: Hospital operators compete for patients, doctors and specialised services.

• Occupancy fluctuations: Lower patient volumes may affect profitability.

• Regulatory requirements: Healthcare operations face medical licensing and compliance obligations.

• Profitability sustainability: The recent financial turnaround needs to be assessed over a longer period.

• IPO valuation: Investors should compare valuation with earnings, growth and listed hospital businesses.

Reviewing the Red Herring Prospectus and its risk disclosures is important before making an investment decision.

Paras Healthcare IPO Important Dates

The schedule follows the announced timetable and may be subject to official updates.

Paras Healthcare IPO: Final Overview

Paras Healthcare IPO offers exposure to India's specialised hospital sector through a network of eight hospitals and a planned expansion strategy.

The company has reported stronger FY2026 financial performance, including a turnaround to profitability and growth in total income. Its proposed debt repayment and hospital development plans will be important factors for future business performance.

At the same time, investors should carefully assess valuation, borrowing levels, expansion risks and the sustainability of earnings.

With the IPO closing on October 23, 2026, investors should check final subscription figures and updated market information before making an investment decision. The reported GMP is only an unofficial indicator and should not be considered a guaranteed listing return.